Last updated on February 2018

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Brief description of study

  1. Objectives
    1. Which organ and how does SGLT2 inhibitor alter insulin sensitivity?
    2. How does SGLT2 inhibitor increase glucagon levels and hepatic glucose production?

Detailed Study Description

2. Clinical hypothesis

  1. SGLT2 inhibitor ameliorates fatty liver and obesity.
  2. SGLT2 inhibitor stimulates sympathetic activity.
  3. SGLT2 inhibitor increases glucagon secretion.
  4. SGLT2 inhibitor enhances lipolysis and hepatic glucose production.

Clinical Study Identifier: NCT02649465

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.